Ayala Pharmaceuticals Inc (ADXS)

[Traderbx]

More tumor mutations equals higher success rate with cancer immunotherapy drugs

Analyzing 27 different cancer types for which both pieces of information were available, the researchers found a strong correlation: the higher a cancer types mutational burden tends to be, the more likely it is to respond to checkpoint inhibitors. More than half of the differences in how well cancers responded to immune checkpoint inhibitors could be explained by the mutational burden of that cancer.

The idea that a tumor type with more mutations might be easier to treat than one with fewer sounds a little counterintuitive. It's one of those things that doesn't sound right when you hear it, says Hopkins. But with immunotherapy, the more mutations you have, the more chances the immune system has to recognize the tumor.


https://www.eurekalert.org/pub_releases/2017-12/jhm-mtm122017.php?utm_content=buffer7cf03&utm_medium=social&utm_source=twitter.com&utm_campaign=buffer